If you want a dialogue based on facts, then you should start using them - instead of the conjecture of most of your comments. You do not know the basis of the Kangio CRL - the Bendeka patents can (and will) be supported - claiming the speed of a 505b2 submission based other drugs does tell me a lot about your 'pedigree', each submission is totally independent of another (and given the past issues around this drug don't expect a quick approval).
Finally you seem to be proclaiming gloom and doom for EGRX based on this one drug, and that's ridiculous. The item Teva is replacing Bendeka with only has about $800M in yearly sales (and then the royalty is 20%). As stated in the previous reply the big prize for EGRX is Ryanodex - which you not surprisingly didn't mention in your post just got NIH backing for an animal clinical for treating Ecstasy and Meth OD's. They should also get approval for EHS shortly. These are very large applications, and is 100% owned by EGRX. Stop your speculative / fact-less comments if you don't want to be challenged on them.